Zoledronic acid is associated with a 25% increased risk of atrial fibrillation during its first year of use for osteoporosis compared to treatment with denosumab, shows a US study published in Journal of Bone and Mineral Research.
Zoledronic acid (ZA) is an effective agent in osteoporosis and malignancy-related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk.
May not be suitable for some people including those with kidney disease, pre-existing esophageal or gastrointestinal conditions, low blood calcium levels (hypocalcemia), or dental disease.
The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01). The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63–1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34– 1.48).
Fever is the most common adverse effect associated with zoledronic acid infusion. Flu-like syndromes including fever, chills, bone pain, and/or arthralgias and myalgias have also occasionally been reported. These symptoms generally did not require treatment and resolved within 24 to 48 hours.
Adverse reactions that have been attributed to zoledronic acid include nausea, fever and itching. Hypocalcaemia will occur in 6% of patients. If this is symptomatic the patient may need to be given calcium gluconate. Renal function should be monitoredas it can be impaired by bisphosphonates.
Vomiting. Constipation. Flu-like symptoms; mild fever sometimes accompanied by malaise, chills, fatigue and flushing. Usually occurs with first treatment with zoledronic acid only.
In conclusion, although a plausible biological connection exists between denosumab and cardiovascular disease, there is no evidence from human trials to support a positive or negative effect on cardiovascular risk, at least at the dose used in osteoporosis therapy.
“There's an association between bone density and cardiovascular disease, meaning the lower your bone density, the higher your risk is of having cardiovascular disease,” says Scott Hummel, MD, Chair-Elect of the American College of Cardiology Geriatric Cardiology Leadership Council.
Bisphosphonates are usually the first choice for osteoporosis treatment. These include: Alendronate (Fosamax), a weekly pill. Risedronate (Actonel), a weekly or monthly pill.
Patients who are treated with zoledronic acid can experience acute phase reactions. Symptoms include fever, diffuse musculoskeletal pain, gastrointestinal effects, and eye inflammation.
Call your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after receiving the medicine. This medicine may cause hypocalcemia (low calcium in the blood). Low blood calcium must be corrected before you receive this medicine.
blood pressure changes either low or high. increased risk of getting an infection due to low levels of white blood cells in the blood. bruising, bleeding gums, or nosebleeds due to low levels of platelets in the blood. difficulty breathing and wheezing.
shortness of breath. These symptoms may mean the level of calcium in your blood has fallen too low. Tell your doctor or pharmacist as soon as possible if you do not feel well while you are having Zoledronic Acid Viatris.
Osteonecrosis (pronounced oss-tee-oh-neh-kro-sis) means death of bone tissue. Osteonecrosis of the jaw bone can occasionally happen when taking bisphosphonates.
Osteoporosis is a disease that causes weak, thinning bones. This leaves the bones at greater risk of breaking. The bones most often affected are the hips, spine, and wrists. Women are 4 times more likely to get osteoporosis than men because of a decrease in estrogen after menopause.
Osteoporosis is the major cause of fractures in postmenopausal women and in older men. Fractures can occur in any bone but happen most often in bones of the hip, vertebrae in the spine, and wrist.
Bone fractures, particularly in the spine or hip, are the most serious complications of osteoporosis. Hip fractures often are caused by a fall and can result in disability and even an increased risk of death within the first year after the injury.
Depending on the body part (whether it's the spine or the hip or another bone in the body), taking an osteoporosis medication will reduce the chances of fracture anywhere from 50 to 70 percent — a substantial reduction in risk, says Khosla. “The side effects are quite rare.
Romosozumab works by speeding up the cells that build bone (osteoblasts), and slowing down the cells that break down bone (osteoclasts). This helps to prevent bone loss.
Romosozumab (Evenity).
This is the newest bone-building medication to treat osteoporosis. It is given as an injection every month at your doctor's office and is limited to one year of treatment.
User Reviews for Zoledronic acid to treat Prevention of Osteoporosis. Zoledronic acid has an average rating of 3.9 out of 10 from a total of 55 reviews for the treatment of Prevention of Osteoporosis. 25% of reviewers reported a positive experience, while 62% reported a negative experience.
Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents.
Administration of Zoledronic Acid Injection 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to renal failure.